Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2011, 3(1), 1232-1252; doi:10.3390/cancers3011232
Review

Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers

1
, 2
 and 3,*
Received: 7 December 2010; in revised form: 25 January 2011 / Accepted: 24 February 2011 / Published: 10 March 2011
(This article belongs to the Special Issue Cancer Stem Cells)
View Full-Text   |   Download PDF [1331 KB, uploaded 10 March 2011]
Abstract: Many studies have highlighted the role cancer stem cells (CSC) play in the development and progression of various types of cancer including lung and esophageal cancer. More recently, it has been proposed that the presence of CSCs affects treatment efficacy and patient prognosis. In reviewing this new area of cancer biology, we will give an overview of the current literature regarding lung and esophageal CSCs and radioresistance of CSC, and discuss the potential therapeutic applications of these findings.
Keywords: cancer stem cells; lung cancer; esophageal cancer; radiation therapy cancer stem cells; lung cancer; esophageal cancer; radiation therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Nguyen, G.H.; Murph, M.M.; Chang, J.Y. Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers. Cancers 2011, 3, 1232-1252.

AMA Style

Nguyen GH, Murph MM, Chang JY. Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers. Cancers. 2011; 3(1):1232-1252.

Chicago/Turabian Style

Nguyen, Giang Huong; Murph, Mandi M.; Chang, Joe Y. 2011. "Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers." Cancers 3, no. 1: 1232-1252.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert